T&L Co Ltd

T&L Co Ltd maintains a strong liquidity position, with a current ratio of 8.3 and cash and equivalents amounting to 73,685,113,950 KRW, indicating a robust ability to meet short-term obligations. The company's debt-to-equity ratio is 0.0, reflecting a conservative capital structure with no long-term debt, which further supports its liquidity profile. In terms of profitability, T&L Co Ltd demonstrates strong returns, with a return on equity (ROE) of 18.93% and a return on assets (ROA) of 17.54%. These figures exceed the typical thresholds for the Medical Equipment, Supplies & Distribution industry, suggesting efficient use of equity and assets to generate profits. The company's revenue is distributed across multiple geographic markets, including the United States, Germany, China, and Dubai, as disclosed in its segments. This diversification helps mitigate regional economic risks and supports stable revenue streams. However, the exact revenue concentration by region is not disclosed in the input data, so further analysis would be required to assess potential over-reliance on any single market. T&L Co Ltd's growth trajectory is supported by its strong operating cash flow of 37,691,797,460 KRW and free cash flow of 18,561,032,100 KRW. Analysts have provided a mean price target of 85,000 KRW, with a mean recommendation of 1.33, indicating a generally positive outlook for the company's future performance. The company's risk assessment indicates low liquidity and dilution risks, with no immediate filing-based flags detected. The absence of long-term debt and the high cash reserves contribute to a stable financial position. Additionally, the low dilution risk suggests that the company is not expected to issue additional shares in the near term, preserving shareholder value. Recent events and filings do not indicate any significant changes in the company's operations or financial strategy. The company continues to focus on its core business of manufacturing and selling wound treatment and orthopedic materials, with no disclosed major strategic shifts or new product launches in the provided data.